Hepion Pharmaceuticals In... (HEPA)
NASDAQ: HEPA
· Real-Time Price · USD
0.07
0.01 (22.59%)
At close: Jun 09, 2025, 3:45 PM
Hepion Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | 109.73K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 30.76K | 12.27K | 18.5K | 18.33K | 18.04K | 18.48K | 17.73K | 18.53K | 22.73K | 23.41K | 23.11K | 21.41K | 18.14K |
Gross Profit | n/a | n/a | n/a | -30.76K | 97.47K | -18.5K | -18.33K | -18.04K | -18.48K | -17.73K | -18.53K | -22.73K | -23.41K | -23.11K | -21.41K | -18.14K |
Operating Income | -1.2M | -4.46M | -8.5M | -5.18M | -10.41M | -10.66M | -14.17M | -13.21M | -9.77M | -8.47M | -20M | -7.25M | -9M | -8.52M | -6.85M | -6.03M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -1.55M | -4.87M | -3.93M | -5.82M | -11.47M | -10.53M | -14.08M | -13.26M | -9.7M | -8.55M | -19.91M | -6.93M | -9.73M | -9.27M | -7.67M | -6.06M |
Net Income | -1.55M | -4.87M | -3.93M | -2.85M | -11.06M | -10.53M | -14.08M | -13.26M | -6.81M | -8.55M | -19.91M | -6.93M | -9.73M | -9.27M | -7.67M | -6.06M |
Selling & General & Admin | 1.79M | 1.7M | 1.37M | 2.61M | 1.78M | 2.15M | 2.28M | 3.41M | 385.76K | 2.73M | 2.43M | 2.94M | 2.09M | 2.72M | 2.67M | 2.53M |
Research & Development | -591.61K | 2.76M | 7.14M | 2.54M | 5.44M | 8.52M | 11.88M | 9.8M | 7.52M | 5.74M | 15.7M | 4.31M | 6.91M | 5.8M | 4.19M | 3.5M |
Other Expenses | n/a | n/a | n/a | n/a | 3.19M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.2M | 4.46M | 8.5M | 5.15M | 7.22M | 10.66M | 14.17M | 13.21M | 7.9M | 8.47M | 18.13M | 7.25M | 9M | 8.52M | 6.85M | 6.03M |
Interest Expense | n/a | n/a | n/a | 4.35K | 2.41K | n/a | 2.35K | 2.32K | 2.51K | 2.27K | 3.18K | 2.21K | 2.18K | 2.13K | 2.49K | 2.05K |
Selling & Marketing Expenses | n/a | n/a | n/a | -30.76K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.2M | 4.46M | 8.5M | 5.18M | 7.22M | 10.66M | 14.17M | 13.21M | 7.9M | 8.47M | 18.13M | 7.25M | 9M | 8.52M | 6.85M | 6.03M |
Income Tax Expense | n/a | n/a | n/a | -2.97M | -409.02K | -137.62K | 2.35K | 2.32K | -2.88M | 82.27K | 3.18K | 2.21K | 2.18K | 2.13K | 2.49K | 2.05K |
Shares Outstanding (Basic) | 139.17K | 134K | 115K | 101K | 88K | 76K | 76K | 76K | 52K | 76K | 76K | 76K | 76K | 76K | 76K | 52K |
Shares Outstanding (Diluted) | 139.17K | 134.38K | 115.98K | 101.45K | 88.13K | 76.77K | 76.53K | 76.23K | 76.23K | 76.23K | 76.23K | 76.23K | 76.29K | 76.22K | 76.22K | 52.16K |
EPS (Basic) | -12.59 | -36.21 | -33.84 | -28.13 | -125.49 | -137.13 | -183.97 | -173.95 | -130.51 | -112.13 | -261.2 | -90.91 | -127.43 | -121.61 | -100.59 | -116.25 |
EPS (Diluted) | -12.59 | -36.21 | -33.84 | -28.13 | -125.49 | -137.13 | -183.97 | -173.95 | -130.51 | -112.13 | -261.2 | -90.91 | -127.43 | -121.61 | -100.59 | -116.25 |
EBITDA | 3.23M | -4.46M | -8.5M | -5.79M | -11.45M | -10.65M | -14.15M | -13.24M | -9.67M | -8.45M | -19.89M | -6.9M | -9.71M | -9.24M | -7.64M | -6.04M |
EBIT | 3.23M | -4.46M | -8.5M | -5.82M | -11.47M | -10.66M | -14.17M | -13.26M | -9.69M | -8.47M | -19.91M | -6.93M | -9.73M | -9.26M | -7.66M | -6.06M |
Depreciation & Amortization | n/a | n/a | n/a | 30.76K | 12.27K | 18.5K | 18.33K | 18.04K | 18.48K | 17.73K | 18.53K | 22.73K | 23.41K | 23.11K | 21.41K | 18.14K |